China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
 - EconoTimes)
NEW ORLEANS, July 28, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against Allergan, Inc. (NYSE:AGN), if they sold call options, purchased put options and/or sold equity forward contracts of the Company between February 25, 2014 and April 21, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you sold call options, purchased put options and/or sold equity forward contracts of Allergan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nyse-agn to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 29, 2017.
About the Lawsuit
Allergan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The Complaint asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 relating to the attempted acquisition of Allergan by Valeant and its affiliates in 2014 in which certain Defendants traded on material non-public information relating to the proposed acquisition, which caused investors to sell call options and equity forward contracts at artificially deflated prices and purchase put options at artificially inflated prices.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
